Concert Genetic Testing: Prenatal Diagnosis (via Amniocentesis, CVS, or PUBS) and Pregnancy Loss

Covers prenatal diagnostic genetic testing via amniocentesis, chorionic villus sampling (CVS), or percutaneous umbilical blood sampling (PUBS), and genetic analysis of products of conception to diagnose fetal chromosomal and single‑gene disorders or determine causes of isolated or recurrent pregnancy loss in pregnancies at increased risk (e.g., abnormal screening, abnormal ultrasound, or prior aneuploidy). Coverage is contingent on specimen adequacy (fresh POC/fetal/placental tissue), may be limited by cell culture failure or maternal cell contamination, generally requires a documented familial pathogenic variant for targeted molecular testing, and restricts or deems investigational certain tests/indications (e.g., CMA, karyotype, exome/genome) unless policy‑specific criteria or prior negative testing are met.

"Prenatal diagnostic testing to identify genetic conditions in fetuses at increased risk based on abnormal prenatal screening results."